14P - Adipose tissue-derived stem cells provide an advantageous tumor microenvironment in gastric cancer

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cancer biology
Gastric Cancer
Presenter Jun Kinoshita
Citation Annals of Oncology (2016) 27 (suppl_9): ix1-ix8. 10.1093/annonc/mdw573
Authors J. Kinoshita1, S. Fushida1, S. Harada2, K. Oyama1, T. Yamaguchi1, A. Hirose1, K. Okamoto1, K. Nakamura1, T. Miyashita1, H. Tajima1, H. Takamura1, I. Ninomiya1, T. Ohta1
  • 1Gastroenterological Surgery, Kanazawa University, 920-8641 - Kanazawa/JP
  • 2Center For Biomedical Research And Education, Kanazawa University, 920-8641 - Kanazawa/JP



Although recent evidence indicates the effect of tissue-resident stem cells located in the surrounding healthy tissue on tumor progression, little is known regarding the influence of adipose-tissue derived stem cells (ASCs) in gastric cancer.


ASCs were isolated from surgical specimens of human omentum. Omental specimens were obtained from patients undergoing elective abdominal surgery according to procedures approved by the IRB of Kanazawa University. Informed consent was obtained from all patients. Female athymic BALB/c nu/nu mice were randomized into two treatment groups: (1) subcutaneous injection of MKN45 human gastric cancer cells or (2) subcutaneous injection of MKN45 mixed directly with ASCs. Tumor growth and volumes over the ensuing 2 weeks were assessed and immunohistochemistry was performed to investigate the influence of ASCs engrafted in tumor microenvironment.


At 2 weeks after injection, the mean tumor volume in the MKN45/ASCs co-injection group (427.3±104.3 mm3) was significantly higher than that in MKN45- only group (194.6±35.1mm3). The stroma in co-inoculated tumors consisted of fibrotic tissue, and the fibrous area was measured semi-quantitatively by Azan staining. The co-injection group showed a significant low ratio of fibrosis when compared with the MKN45-only group (p 


Our study revealed for the first time that ASCs subcutaneously co-injected with prostate cancer cells engraft and promote tumor progression.

Clinical trial indentification

Legal entity responsible for the study

Jun Kinoshita


Grant sponsor: Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research; Grant number: 15K19876


All authors have declared no conflicts of interest.